Reviewing BioNxt Solutions (OTCMKTS:BNXTF) & BioVie (NASDAQ:BIVI)

BioVie (NASDAQ:BIVI) and BioNxt Solutions (OTCMKTS:BNXTF) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.

Insider and Institutional Ownership

4.6% of BioVie shares are owned by institutional investors. 0.9% of BioVie shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for BioVie and BioNxt Solutions, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1	0	0	1	2.50
BioNxt Solutions	0	0	0	0	0.00

Earnings and Valuation

This table compares BioVie and BioNxt Solutions”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$17.54 million	($79.10)	-0.02
BioNxt Solutions	$20,000.00	3,172.40	-$3.88 million	($0.04)	-13.70

BioNxt Solutions has higher revenue and earnings than BioVie. BioNxt Solutions is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

BioVie has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, BioNxt Solutions has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

Profitability

This table compares BioVie and BioNxt Solutions’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-85.61%	-77.08%
BioNxt Solutions	N/A	N/A	-815.86%

Summary

BioVie beats BioNxt Solutions on 6 of the 11 factors compared between the two stocks.

About BioVie

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

About BioNxt Solutions

BioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.